Pattern Bioscience, Inc., an Austin, Texas-based in vitro diagnostics company, raised $9M in Series B-1 funding.
The round was led by Illumina Ventures with participation from Omnimed Capital. As part of the transaction, Nick Naclerio, Founding Partner of Illumina Ventures, will join Pattern’s Board of Directors.
The company intends to use the funds to accelerate development and validation of its transformational bacterial testing technology.
Founded in 2016 and led by CEO Nick Arab, Pattern Bioscience is an in vitro diagnostics company focused on antibiotic resistance. The company is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. Digital CultureTM’s single cell analysis platform uses digital cell reactors combined with machine learning to rapidly diagnose complex bacterial infections. The platform, which produces millions of measurements per run, will zoom into the real-time antibiotic response of individual bacterial cells within the first critical hours of illness.